'Relapsed refractory' diaporamas de présentation

Integration of Novel Therapies in WM and CLL : When and How to Use Them

682 views • 55 slides

Experimental Agents for Relapsed/Refractory Myeloma - Current Trials in Context

Experimental Agents for Relapsed/Refractory Myeloma - Current Trials in Context Kenneth C. Anderson, M.D. Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute Harvard Medical School. Conflict of Interest: Kenneth C. Anderson, M.D.

532 views • 36 slides

Mantle Cell Lymphoma (MCL): Approach to Upfront Treatment

Mantle Cell Lymphoma (MCL): Approach to Upfront Treatment. Lauren C Pinter-Brown, MD Director, UCLA Lymphoma Program Clinical Professor of Medicine Geffen School of Medicine at UCLA. Interest in Topics Related to the Treatment of Patients with CTCL or PTCL (Percent Responding 9 or 10).

997 views • 28 slides

Steven M Horwitz Assistant Attending Memorial Sloan Kettering Cancer Center New York, New York

Steven M Horwitz Assistant Attending Memorial Sloan Kettering Cancer Center New York, New York. Clofarabine for T-cell Lymphomas Not as yet preliminary results from a phase I/II trial. clofarabine structure . C. l. Clofarabine is a Hybrid Purine Nucleoside Analog. N. H. N. H. N. N. H.

127 views • 12 slides

Shah JJ et al. Proc ASH 2012; Abstract 74.

A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma. Shah JJ et al. Proc ASH 2012; Abstract 74. Background.

255 views • 11 slides